Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AV-OVA-1
- Development stage
- Phase 2
- Lead developer
- Aivita Biomedical
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
AV-OVA-1 is an autologous dendritic cell-based immunotherapy developed by Aivita Biomedical for the treatment of advanced or recurrent ovarian cancer. The therapeutic process involves isolating a patient's own dendritic cells and pulsing them with autologous tumor antigens derived from the patient's tumor-initiating cells (cancer stem cells). This personalized approach is designed to train the patient's immune system to identify and destroy the self-renewing cells responsible for tumor growth and chemoresistance. AV-OVA-1 is typically administered as a series of subcutaneous injections following primary debulking surgery and frontline chemotherapy, aiming to prevent recurrence and improve overall survival by targeting the root of the malignancy.
- Other names
- Aivita ovarian cancer vaccine
Beyond the preview
Go deeper on AV-OVA-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AV-OVA-1.